The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    January 2020

  • Pages
    473

  • View Count
    4422

Example Insights

Ophthalmic Drugs Contract Manufacturing Market-Context Ophthalmic Drugs Contract Manufacturing Market-Example highlight Ophthalmic Drugs Contract Manufacturing Market-Different scales of operation Ophthalmic Drugs Contract Manufacturing Market-Different Geographies
Ophthalmic Drugs Contract Manufacturing Market-Types of containers Ophthalmic Drugs Contract Manufacturing Market-Distribution by location Ophthalmic Drugs Contract Manufacturing Market-Competitiveness anaysis Ophthalmic Drugs Contract Manufacturing Market-Clinical research landscape
Ophthalmic Drugs Contract Manufacturing Market-Capacity analysis Ophthalmic Drugs Contract Manufacturing Market-Demand & supply analysis Ophthalmic Drugs Contract Manufacturing Market-Market Forecast 	Ophthalmic Drugs Contract Manufacturing Market-Futuer Forecast

 

Overview

Ophthalmic diseases, such as age-related macular degeneration, cataract, diabetic retinopathy, dry eye and glaucoma, are considered among the leading causes of vision loss across the globe. According to the World Health Organization’s report published in 2019, at least 2.2 billion individuals in the world are reported to be visually impaired. In fact, blindness caused due to multiple reasons, is projected to increase to 75 million affected individuals by 2020. Moreover, current estimates indicate that the total economic burden related to vision loss is expected to reach approximately USD 384 billion by 2030, in the US alone. The rise in incidence and prevalence of chronic eye disorders has prompted the medical research community to actively develop a variety of ophthalmic drugs / therapies. The current ophthalmic diseases treatment landscape is characterized by a number of blockbuster therapies, namely ALPHAGAN®, COSOPT®, LUMIGAN®, PAZEO®, RESTASIS®, TRAVATAN Z®, and XALATAN®, and a robust pipeline of over 400 candidate drugs in various stages of clinical development, designed for the treatment of approximately 1,000 chronic eye disorders.  

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of innovator companies have demonstrated a preference to outsource certain aspects of ophthalmic drug development and production operations to contract service providers. Contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are known to offer significant benefits, which include reduction in capital investment, access to larger production capacities, reductions in time-to-market and also guarantee a significant degree of commercial risk mitigation. Since 2000, more than 75 new ophthalmology focused CMOs have been established. Amidst the tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry. This has caused many service providers to actively expand their respective service portfolios, either through strategic acquisitions or facility / capability expansions. Over time, many CMOs / CDMOs claim to have developed end-to-end service capabilities, ranging from drug development (including preliminary R&D, preclinical studies and clinical trials), to regulatory filings, and commercial scale production.

In light of the aforementioned facts, several CMOs based in the Asia-Pacific region (such as India, China and Japan) play a critical role in the global ophthalmic API and FDF manufacturing. We believe that, the changing supply chain scenario due to the recent COVID-19 pandemic is likely to have a prominent impact on the global contract manufacturing industry, including China, in the short term. As pharma companies resume full-scale operation after the coronavirus outbreak, the demand for large-scale contract manufacturing is expected to increase significantly.

Scope of the Report

The ‘Ophthalmic Drugs Contract Manufacturing Market, 2020-2030’ report features an extensive study of the contract services market for ophthalmic products and solutions. It is worth mentioning that the study primarily focuses on small molecule active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), including ophthalmic drops, emulsions, gels, injections, lotions, ointments, suspensions, and tablets / capsules. It features in-depth analyses, highlighting the capabilities of a diverse set of CMOs and CDMOs. Amongst other elements, the report includes:

  • A detailed review of the ophthalmic drugs contract manufacturing market landscape, featuring a list of over 240 CMOs and analysis based on a number of relevant parameters, such as year of establishment, company size, geographical location, scale of operation (preclinical, pilot, clinical, and commercial), type of product (APIs and FDFs), type of FDF manufactured (solids, semi-solids, liquids, suspensions, and injectables), type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, sachets / pouches, blister packing, and other forms), type of service(s) offered (pre-formulation, drug formulation, method validation, process development, analytical testing, stability studies, technology transfer, scale-up, fill / finish, and regulatory support), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.
  • A company competitiveness analysis, highlighting prominent ophthalmic drug contract manufacturers based on supplier strength (which was calculated considering the size of employee base of a company and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities, and number of regulatory accreditations / certifications). 
  • Elaborate profiles of key players based in North America, Europe and Asia-Pacific that offer a diverse range of capabilities for the development, manufacturing and packaging of ophthalmic drug products. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook. 
  • A detailed clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products, highlighting prevalent trends across parameters, such as current trial status, trial registration year, enrolled patient population and trial location, phase of development, study design, leading industry and non-industry players (in terms of number of trials undertaken / conducted), study focus, and key disease indications  (in terms of number of trials undertaken / conducted). 
  • An informed estimate of the annual commercial demand for ophthalmic APIs and drug FDFs (in million litres), taking into account the top 30 small molecule-based ophthalmic drugs; the analysis takes into consideration the target patient population, dosing frequency and dose strength of the aforementioned products. The annual clinical demand for ophthalmic drug products was also estimated, taking into account ongoing and planned clinical trials.
  • A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized, and large-sized CMOs) in the market, based on data gathered via secondary and primary research. It also provides the likely distribution of the global ophthalmic product-related manufacturing capacity available across different types of companies (small-sized, mid-sized, and large-sized), scales of operation (preclinical, clinical and commercial), types of FDFs manufactured (ampoules / vials, glass / plastic bottles, and ointment tubes), and key geographical regions (North America, Europe, and Asia-Pacific).
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to ophthalmic drug developers.
  • A discussion on the emerging trends and potential market drivers, such as the growing ophthalmic drugs / therapies pipeline, rise in outsourcing activity for sterile manufacturing operations, adoption of innovative technologies and increasing opportunities in the Asia-Pacific region, which are likely to impact the evolution of the market in the coming years.
  • A detailed list of over 55 ophthalmic medical device contract manufacturers, along with information on year of establishment, company size, geographical location, key application area(s) (diagnostics, drug delivery, therapeutics, and others), type of manufacturing service(s) offered (design, component manufacturing, assembly, prototype development, sterilization, quality assurance, and packaging), type of additional service(s) offered (consultancy, documentation, inspection / testing, labelling, logistics, project management, regulatory support, repair, warehouse / storage, and others), scale of operation (pilot and commercial), device class-related expertise (class I, class II and class III), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as growth of the overall ophthalmic drugs market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] type of product (APIs and FDFs), [B] type of FDF manufactured (solids, semi-solids, and liquids / suspensions), [C] type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, blister packing, and other forms), [D] scale of manufacturing (preclinical, clinical, and commercial), [E] company size (small sized, mid-sized, and large-sized companies), [F] key disease indications (age-related macular degeneration, glaucoma, uveitis, dry eye, and other disease segments), and [G] key geographical regions, covering North America (the US, Canada and Mexico), Europe (the UK, Germany, France, Spain, Italy and rest of Europe), and Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific). To account for the uncertainties associated with the growth of the ophthalmic drugs contract manufacturing market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions presented in this study were influenced by inputs (through an industry-wide survey) of several key players in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals: 

  • Rahul Gupta (Chief Executive Officer, Selvok Pharmaceutical)
  • Vivek Partheeban (Chief Operating Officer, Caplin Point Laboratories) and Ashok Partheeban (Director, Latin American Operations, Caplin Point Laboratories) 
  • Stuart Smith (Managing Director, Phytex Australia)
  • Iranna Bavalatti (General Manager, Gland Pharma)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What is the clinical research landscape of investigational ophthalmic drugs?
  • What percentage of ophthalmic drug manufacturing operations are outsourced to service providers?
  • What are the preferred primary packaging formats / fill finish containers of ophthalmic drugs?
  • Who are the leading contract manufacturers of ophthalmic APIs and drug FDFs, across the globe?
  • What are the key challenges faced by ophthalmic drug contract manufacturers?
  • What is the annual, clinical and commercial demand for ophthalmic drugs?
  • What is the current, installed manufacturing capacity for ophthalmic drugs?
  • What are the anticipated future trends related to ophthalmic drug manufacturing? 
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the ophthalmic drugs contract manufacturing market in the mid to long term. 

Chapter 3 presents a general overview of the field of ophthalmology, including information on various chronic eye disorder and the economic burden associated with such conditions. Further, it features a detailed discussion on a variety of ophthalmic drug formulations and affiliated primary packaging. It also provides inputs on the various benefits and challenges associated with the aforementioned products across different types of ophthalmic diseases. Further, the chapter features a brief overview of contract manufacturing and a discussion on the need for outsourcing within the ophthalmic drugs market. In addition, it includes a list of commonly outsourced aseptic manufacturing services and highlights the key factors that need to be considered during the selection of potential CMOs, along with information on key challenges that are currently associated within this market. The chapter concludes with a discussion on the key growth drivers and roadblocks related to ophthalmic drugs contract manufacturing, as well as upcoming trends that the field is expected to witness in the coming years.

Chapter 4 provides a comprehensive overview on the global ophthalmic drugs contract manufacturing landscape. It includes information related to over 240 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market based on a number of parameters, such as year of establishment, company size, geographical location, scale of operation (preclinical, pilot, clinical, and commercial), type of product (APIs and FDFs), type of FDF manufactured (solids, semi-solids, liquids, suspensions, and injectables), type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, sachets / pouches, blister packing, and other forms), type of service(s) offered (pre-formulation, drug formulation, method validation, process development, analytical testing, stability studies, technology transfer, scale-up, fill / finish, and regulatory support), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.

Chapter 5 features an insightful company competitiveness analysis of both ophthalmic API and drug FDF contract manufacturers based in North America, Europe and Asia-Pacific, that we came across during our research. The analysis compares companies within each business operation and geography on the basis of supplier strength (which was calculated considering the size of employee base of a company and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities, and number of regulatory accreditations / certifications).

Chapter 6 includes detailed profiles of some of the key players that are active in the ophthalmic drugs contract manufacturing market in North America. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.

Chapter 7 includes detailed profiles of some of the key players that are active in the ophthalmic drugs contract manufacturing market in Europe. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.

Chapter 8 includes detailed profiles of some of the key players that are active in the ophthalmic drugs contract manufacturing market in Asia-Pacific. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.

Chapter 9 provides a comprehensive clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and trial location, phase of development, study design, leading industry and non-industry players (in terms of number of trials undertaken / conducted), study focus, and key disease indications (in terms of number of trials undertaken / conducted).

Chapter 10 features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of ophthalmic drug products. The analysis takes into consideration the individual manufacturing capacities of various stakeholders (small-sized, mid-sized, and large-sized CMOs) in the market, using data from both secondary and primary research. It also examines the likely distribution of the global ophthalmic product-related manufacturing capacity available across different types of companies (small-sized, mid-sized, and large-sized), scales of operation (preclinical, clinical and commercial), types of FDFs manufactured (ampoules / vials, glass / plastic bottles, and ointment tubes), and key geographical regions (North America, Europe, and Asia-Pacific).

Chapter 11 features a detailed estimate of the annual demand for ophthalmic APIs and drug FDFs (in million liters), offering an informed opinion on the required scale of supply (in terms of ophthalmic drug contract manufacturing services). In order to estimate the annual commercial demand, we considered the top 30 small molecule-based ophthalmic drugs; the analysis takes into consideration the target patient population, dosing frequency and dose strength of the aforementioned products. The annual clinical demand for ophthalmic drug products was also estimated, taking into account the ongoing and planned clinical trials. 

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of the ophthalmic drugs contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of product (APIs and FDFs), [B] type of FDF manufactured (solids, semi-solids, and liquids / suspensions), [C] type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, blister packing, and other forms), [D] scale of manufacturing (preclinical / clinical and commercial), [E] company size (small sized, mid-sized, and large-sized companies), [F] key disease indications (age-related macular degeneration, glaucoma, uveitis, dry eye, and other disease segments), and [G] key geographical regions, covering North America (the US, Canada and Mexico), Europe (the UK, Germany, France, Spain, Italy and rest of Europe), and Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific). 

Chapter 13 is a case study comparing the key characteristics of large and small molecule ophthalmic drugs, along with information on the steps involved in their respective manufacturing processes.

Chapter 14 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of ophthalmic drugs contract manufacturing market, under a comprehensive SWOT framework.

Chapter 15 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in the ophthalmic drugs contract manufacturing market.

Chapter 16 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Rahul Gupta (Chief Executive Officer, Selvok Pharmaceutical), Vivek Partheeban (Chief Operating Officer, Caplin Point Laboratories) and Ashok Partheeban (Director, Latin American Operations, Caplin Point Laboratories), Stuart Smith (Managing Director, Phytex Australia), and Iranna Bavalatti (General Manager, Gland Pharma).

Chapter 17 highlights the emerging trends and potential market drivers for ophthalmic drug contract manufacturers. It highlights the various opportunities associated with the growing ophthalmic drugs / therapies pipeline, increase in outsourcing of aseptic manufacturing operations, adoption of innovative technologies and increasing opportunities in the Asia-Pacific region, which are likely to impact the evolution of the market in the coming years. 

Chapter 18 is an appendix, which provides a comprehensive list of over 55 ophthalmic medical device contract manufacturers, along with information on year of establishment, company size, geographical location, key application area(s) (diagnostics, drug delivery, therapeutics, and others), type of manufacturing service(s) offered (design, component manufacturing, assembly, prototype development, sterilization, quality assurance, and packaging), type of additional service(s) offered (consultancy, documentation, inspection / testing, labelling, logistics, project management, regulatory support, repair, warehouse / storage, and others), scale of operation (pilot and commercial), device class-related expertise (class I, class II and class III), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 20 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Introduction to Ophthalmology
3.2.1. Anatomy of the Human Eye
3.2.2. Chronic Eye Conditions and Associated Economic Burden

3.3. Common Ophthalmic Drug Dosage Forms
3.3.1. Types of Oral Drug Formulations
3.3.1.1. Tablets
3.3.1.2. Capsules
3.3.1.3. Eye Supplements

3.3.2. Types of Semi-solid Formulations
3.3.2.1. Ointments
3.5.2.2. Gels
3.5.2.3. Emulsions

3.3.3. Types of Liquid Drug Formulations
3.3.3.1. Solutions
3.3.3.2. Suspensions
3.5.3.1. Sterile Injectables

3.3.4. Intraocular Inserts

3.4. Common Primary Packaging Formats for Ophthalmic Drugs

3.5. Overview of Contract Manufacturing
3.6. Outsourcing in the Ophthalmology Industry
3.6.1. Need for Outsourcing
3.6.2. Commonly Outsourced Operations
3.6.3. Guidelines for Selecting a Contract Manufacturing Organization (CMO) Partner
3.6.4. Advantages of Outsourcing Manufacturing Operations
3.6.5. Challenges Associated with Ophthalmic Drugs Contract Manufacturing
3.6.6. Growth Drivers and Roadblocks to Ophthalmic Drugs Contract Manufacturing
3.6.7. Recent Developments and Upcoming Trends

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Ophthalmic Drug Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Geographical Location
4.2.5. Analysis by Location of Manufacturing Facilities
4.2.6. Analysis by Type of Product
4.2.7. Analysis by Type of FDF Manufactured
4.2.8. Analysis by Type of Primary Packaging
4.2.9. Analysis by Type of Service(s) Offered
4.2.10. Analysis by Regulatory Accreditations / Certifications

5. COMPANY COMPETITVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Methodology
5.3. Competitiveness Analysis: Ophthalmic API Contract Manufacturers
5.3.1. Ophthalmic API Contract Manufacturers in North America
5.3.2. Ophthalmic API Contract Manufacturers in Europe
5.3.3. Ophthalmic API Contract Manufacturers in Asia-Pacific

5.4. Competitiveness Analysis: Ophthalmic Drug FDF Contract Manufacturers
5.4.1. Ophthalmic Drug FDF Contract Manufacturers in North America
5.4.2. Ophthalmic Drug FDF Contract Manufacturers in Europe
5.4.3. Ophthalmic Drug FDF Contract Manufacturers in Asia-Pacific

6. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. Akorn
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Service Portfolio
6.2.4. Recent Developments and Future Outlook

6.3. Catalent
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Service Portfolio
6.2.4. Recent Developments and Future Outlook

6.4. Cayman Chemical
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Recent Developments and Future Outlook

6.5. Pillar5 Pharma
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. Sterling Pharmaceutical Services
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Recent Developments and Future Outlook

7. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN EUROPE: COMPANY PROFILES
7.1. Chapter Overview
7.2. FARMIGEA
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. Lomapharm
7.3.1. Company Overview
7.3.2. Service Portfolio
7.3.3 Recent Developments and Future Outlook

7.4. Medichem
7.4.1. Company Overview
7.4.2. Service Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. Recipharm
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. Service Portfolio
7.5.4. Recent Developments and Future Outlook

7.6. Salvat
7.6.1. Company Overview
7.6.2 Service Portfolio
7.6.3. Recent Developments and Future Outlook

8. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN ASIA-PACIFIC: COMPANY PROFILES
8.1. Chapter Overview
8.2. Akums
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Recent Developments and Future Outlook

8.3. Bal Pharma
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook

8.4. Entod Pharmaceuticals
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. Recent Developments and Future Outlook

8.5. Glenmark Pharmaceuticals
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. Recent Developments and Future Outlook

8.6. Indiana Ophthalmics
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Recent Developments and Future Outlook

8.7. Sunways India
8.7.1. Company Overview
8.7.2. Service Portfolio
8.7.3. Recent Developments and Future Outlook

9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Ophthalmic Drug Trial Analysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Geographical Analysis by Number of Clinical Trials
9.3.3. Geographical Analysis by Enrolled Patient Population
9.3.4. Analysis by Phase of Development
9.3.5. Analysis by Trial Recruitment Status
9.3.6. Analysis by Type of Sponsor / Collaborator
9.3.7. Most Active Players in Terms of Number of Registered Trials
9.3.8. Analysis by Type of Intervention
9.3.9. Analysis by Trial Focus
9.3.10. Analysis by Target Indication
9.3.11. Benchmark Analysis of Active Industry Players

10. CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Ophthalmic API Contract Manufacturers: Global Production Capacity (by Volume)
10.3.1. Analysis by Geography
10.3.1.1. Overall Production Capacity in North America (by Volume)
10.3.1.2. Overall Production Capacity in Europe (by Volume)
10.3.1.3. Overall Production Capacity in Asia-Pacific (by Volume)

10.3.2. Analysis by Scale of Operation
10.3.2.1. Overall Lab Scale Production Capacity (by Volume)
10.3.2.2. Overall Clinical Scale Production Capacity (by Volume)
10.3.2.3. Overall Commercial Scale Production Capacity (by Volume)

10.3.3. Analysis by Company Size
10.3.3.1. Overall Production Capacity of Small-sized Companies (by Volume)
10.3.3.2. Overall Production Capacity of Mid-sized Companies (by Volume)
10.3.3.3. Overall Production Capacity of Large-sized Companies (by Volume)

10.4. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity
10.4.1. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity (by Volume)
10.4.1.1. Analysis by Geography
10.4.1.1.1. Overall Production Capacity in North America (by Volume)
10.4.1.1.2. Overall Production Capacity in Europe (by Volume)
10.4.1.1.3. Overall Production Capacity in Asia-Pacific (by Volume)

10.4.1.2. Analysis by Scale of Operation
10.4.1.2.1. Overall Lab Scale Production Capacity (by Volume)
10.4.1.2.2. Overall Clinical Scale Production Capacity (by Volume)
10.4.1.2.3. Overall Commercial Scale Production Capacity (by Volume)

10.4.1.3. Analysis by Company Size
10.4.1.3.1. Overall Production Capacity of Small-sized Companies (by Volume)
10.4.1.3.2. Overall Production Capacity of Mid-sized Companies (by Volume)
10.4.1.3.3. Overall Production Capacity of Large-sized Companies (by Volume)

10.4.1.4. Analysis by Type of Primary Packaging
10.4.1.4.1. Overall Production Capacity of Ampoules / Vials (by Volume)
10.4.1.4.2. Overall Production Capacity of Glass / Plastic Bottles (by Volume)
10.4.1.4.3. Overall Production Capacity of Ointment Tubes (by Volume)

10.4.2. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity (by Number of Units)
10.4.2.1. Analysis by Geography
10.4.2.1.1. Overall Production Capacity in North America (by Number of Units)
10.4.2.1.2. Overall Production Capacity in Europe (by Number of Units)
10.4.2.1.3. Overall Production Capacity in Asia-Pacific (by Number of Units)

10.4.2.2. Analysis by Scale of Operation
10.4.2.2.1. Overall Lab Scale Production Capacity (by Number of Units)
10.4.2.2.2. Overall Clinical Scale Production Capacity (by Number of Units)
10.4.2.2.3. Overall Commercial Scale Production Capacity (by Number of Units)

10.4.2.3. Analysis by Company Size
10.4.2.3.1. Overall Production Capacity of Small-sized Companies (by Number of Units)
10.4.2.3.2. Overall Production Capacity of Mid-sized Companies (by Number of Units)
10.4.2.3.3. Overall Production Capacity of Large-sized Companies (by Number of Units)

10.4.2.4. Analysis by Type of Primary Packaging
10.4.2.4.1. Overall Production Capacity of Ampoules / Vials (by Number of Units)
10.4.2.4.2. Overall Production Capacity of Glass / Plastic Bottles (by Number of Units)
10.4.2.4.3. Overall Production Capacity of Ointment Tubes (by Number of Units)

11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Global Commercial Demand for Ophthalmic Drugs Contract Manufacturing
11.3.1. Commercial Demand for Ophthalmic API Contract Manufacturing
11.3.1.1. Analysis by Geography
11.3.1.2. Analysis by Scale of Operation
11.3.1.3. Analysis by Target Indication

11.3.2. Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing
11.3.2.1. Analysis by Geography
11.3.2.2. Analysis by Scale of Operation
11.3.2.3. Analysis by Target Indication
11.3.2.4. Analysis by Type of Primary Packaging

11.4. Global Clinical Demand for Ophthalmic Drugs Contract Manufacturing
11.4.1. Clinical Demand for Ophthalmic API Contract Manufacturing
11.4.1.1. Analysis by Geography
11.4.1.2. Analysis by Scale of Operation
11.4.1.3. Analysis by Target Indication

11.4.2. Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing
11.4.2.1. Analysis by Geography
11.4.2.2. Analysis by Scale of Operation
11.4.2.3. Analysis by Target Indication
11.4.2.4. Analysis by Type of Primary Packaging

11.5. Demand and Supply Analysis

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Overall Ophthalmic Drugs Contract Manufacturing Market, 2020-2030

12.4. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Product
12.4.1. Ophthalmic API Contract Manufacturing Market, 2020-2030
12.4.2. Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030
12.4.2.1. Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of FDF Manufactured
12.4.2.1.1. Ophthalmic Drugs Contract Manufacturing Market for Solids, 2020-2030
12.4.2.1.2. Ophthalmic Drugs Contract Manufacturing Market for Semi-solids, 2020-2030
12.4.2.1.3. Ophthalmic Drugs Contract Manufacturing Market for Liquids / Suspensions, 2020-2030

12.4.2.2. Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of Primary Packaging
12.4.2.2.1. Ophthalmic Drugs Contract Manufacturing Market for Ampoules / Vials, 2020-2030
12.4.2.2.2. Ophthalmic Drugs Contract Manufacturing Market for Glass / Plastic Bottles, 2020-2030
12.4.2.2.3. Ophthalmic Drugs Contract Manufacturing Market for Ointment Tubes, 2020-2030
12.4.2.2.4. Ophthalmic Drugs Contract Manufacturing Market for Blister Packing, 2020-2030
12.4.2.2.5. Ophthalmic Drugs Contract Manufacturing Market for Other Packaging Forms, 2020-2030

12.5. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Target Disease Indication
12.5.1. Ophthalmic Drugs Contract Manufacturing Market for Age-related Macular Degeneration, 2020-2030
12.5.2. Ophthalmic Drugs Contract Manufacturing Market for Dry Eye, 2020-2030
12.5.3. Ophthalmic Drugs Contract Manufacturing Market for Glaucoma, 2020-2030
12.5.4. Ophthalmic Drugs Contract Manufacturing Market for Uveitis, 2020-2030
12.5.5. Ophthalmic Drugs Contract Manufacturing Market for Other Eye Disorders, 2020-2030

12.6. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
12.6.1. Ophthalmic Drugs Contract Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030
12.6.2. Ophthalmic Drugs Contract Manufacturing Market for Commercial Scale Operations, 2020-2030

12.7. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Size of Manufacturers
12.7.1. Ophthalmic Drugs Contract Manufacturing Market for Small-sized Companies, 2020-2030
12.7.2. Ophthalmic Drugs Contract Manufacturing Market for Mid-sized Companies, 2020-2030
12.7.3. Ophthalmic Drugs Contract Manufacturing Market for Large-sized Companies, 2020-2030

12.8. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Geographical Regions
12.8.1. Ophthalmic Drugs Contract Manufacturing Market in North America, 2020-2030
12.8.1.1. Ophthalmic Drugs Contract Manufacturing Market in the US, 2020-2030
12.8.1.2. Ophthalmic Drugs Contract Manufacturing Market in Canada, 2020-2030
12.8.1.3. Ophthalmic Drugs Contract Manufacturing Market in Mexico, 2020-2030

12.8.2. Ophthalmic Drugs Contract Manufacturing Market in Europe, 2020-2030
12.8.2.1. Ophthalmic Drugs Contract Manufacturing Market in the UK, 2020-2030
12.8.2.2. Ophthalmic Drugs Contract Manufacturing Market in Germany, 2020-2030
12.8.2.3. Ophthalmic Drugs Contract Manufacturing Market in France, 2020-2030
12.8.2.4. Ophthalmic Drugs Contract Manufacturing Market in Spain, 2020-2030
12.8.2.5. Ophthalmic Drugs Contract Manufacturing Market in Italy, 2020-2030
12.8.2.6. Ophthalmic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030

12.8.3. Ophthalmic Drugs Contract Manufacturing Market in Asia-Pacific, 2020-2030
12.8.3.1. Ophthalmic Drugs Contract Manufacturing Market in India, 2020-2030
12.8.3.2. Ophthalmic Drugs Contract Manufacturing Market in China, 2020-2030
12.8.3.3. Ophthalmic Drugs Contract Manufacturing Market in Japan, 2020-2030
12.8.3.4. Ophthalmic Drugs Contract Manufacturing Market in Australia, 2020-2030
12.8.3.5. Ophthalmic Drugs Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030

13. CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE MOLECULE OPHTHALMIC DRUGS / THERAPIES
13.1. Chapter Overview
13.2. Small Molecule Drugs and Biologics
13.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
13.2.2. Comparison of Key Specifications
13.2.3. Comparison of Manufacturing Processes
13.2.4. Comparison of Key Manufacturing-related Challenges

14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Comparison of SWOT Factors

15. SURVEY ANALYSIS
15.1. Chapter Overview
15.2. Overview of Respondents
15.2.1. Seniority Level of Respondents

15.3. Survey Insights
15.3.1. Type of Product
15.3.2. Type of Primary Packaging
15.3.3. Scale of Operation
15.3.4. Manufacturing Capacity
15.3.5. Location of Manufacturing Facilities
15.3.6. Regulatory Accreditations / Certifications of Manufacturing Facilities
15.3.7. Extent of Outsourcing
15.3.8. Current Market Opportunity

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Selvok Pharmaceutical
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Rahul Gupta, Chief Executive Officer

16.3. Caplin Point Laboratories
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Vivek Partheeban, Chief Operating Officer and Ashok Partheeban, Director, Latin American Operations

16.4. Phytex Australia
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Stuart Smith, Managing Director

16.5. Gland Pharma
16.5.1. Company Snapshot
16.5.2. Interview Transcript: Iranna Bavalatti, General Manager

17. FUTURE GROWTH OPPORTUNITIES
17.1. Chapter Overview
17.2. Integration / Adoption of New and Innovative Technologies
17.3. Capability and Expertise Expansions by CMOs
17.4. Offshoring Outsourcing Activities
17.5. Growing Investments in Existing Infrastructure
17.6. Evolving Client / Sponsor and CMO / CDMO Relationships
17.7. Business Acquisition and Consolidation Activity
17.8. Challenges Faced by Both Sponsors and Service Providers
17.8.1. Concerns Related to Single Use Systems
17.8.2. Concerns Related to Capacity Fluctuations

18. APPENDIX 1: LIST OF OPHTHALMIC MEDICAL DEVICE CONTRACT MANUFACTURERS

19. APPENDIX 2: TABULATED DATA

20 APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figuers

Figure 3.1 Estimates on the Visually Impaired Population (US), 2019, 2030 and 2050 (in Millions)
Figure 3.2 Classification of Ophthalmic Drug Dosage Forms
Figure 3.3 Advantages and Disadvantages of Tablets
Figure 3.4 Advantages and Disadvantages of Capsules
Figure 3.5 Advantages and Disadvantages of Eye Supplements
Figure 3.6 Advantages and Disadvantages of Ointments
Figure 3.7 Advantages and Disadvantages of Gels
Figure 3.8 Advantages and Disadvantages of Emulsions
Figure 3.9 Advantages and Disadvantages of Solutions
Figure 3.10 Advantages and Disadvantages of Suspensions
Figure 3.11 Advantages and Disadvantages of Sterile Injectables
Figure 3.12 Advantages and Disadvantages of Intraocular Inserts
Figure 3.13 Common Primary Packaging Formats for Ophthalmic Drugs
Figure 3.14 Types of Standalone Contract Service Providers
Figure 3.15 Outsourcing in the Ophthalmology Industry
Figure 3.16 Commonly Outsourced Operations
Figure 3.17 Guidelines for Selecting a CMO Partner
Figure 3.18 Growth Drivers and Roadblocks to Ophthalmic Drugs Contract Manufacturing
Figure 4.1 Ophthalmic Drug Contract Manufacturers: Distribution by Year of Establishment
Figure 4.2 Ophthalmic Drug Contract Manufacturers: Distribution by Company Size
Figure 4.3 Ophthalmic Drug Contract Manufacturers: Distribution by Scale of Operation
Figure 4.4 Ophthalmic Drug Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Figure 4.5 Ophthalmic Drug Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Figure 4.6 Ophthalmic Drug Contract Manufacturers: Distribution by Location of FDF Manufacturing Facilities (Region-Wise)
Figure 4.7 Ophthalmic Drug Contract Manufacturers: Distribution by Location of FDF Manufacturing Facilities (Country-Wise)
Figure 4.8 Ophthalmic Drug Contract Manufacturers: Distribution by Location of API Manufacturing Facilities (Region-Wise)
Figure 4.9 Ophthalmic Drug Contract Manufacturers: Distribution by Location of API Manufacturing Facilities (Country-Wise)
Figure 4.10 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Product
Figure 4.11 Ophthalmic Drug Contract Manufacturers: Distribution by Type of FDF Manufactured
Figure 4.12 Ophthalmic Drug Contract Manufacturers: Distribution by Type of FDF Manufactured and Company Size
Figure 4.13 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Primary Packaging
Figure 4.14 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Service(s) Offered
Figure 4.15 Ophthalmic Drug Contract Manufacturers: Distribution by Regulatory Accreditations / Certifications
Figure 5.1 Competitiveness Analysis of Ophthalmic API Contract Manufacturers in North America
Figure 5.2 Competitiveness Analysis of Ophthalmic API Contract Manufacturers in Europe
Figure 5.3 Competitiveness Analysis of Ophthalmic API Contract Manufacturers in Asia-Pacific
Figure 5.4 Competitiveness Analysis of Ophthalmic Drug FDF Contract Manufacturers in North America
Figure 5.5 Competitiveness Analysis of Ophthalmic Drug FDF Contract Manufacturers in Europe
Figure 5.6 Competitiveness Analysis of Ophthalmic Drug FDF Contract Manufacturers in Asia-Pacific
Figure 6.1 Akorn: Net Revenues, FY 2015-Q3 2019 (USD Million)
Figure 6.2 Akorn: Service Portfolio
Figure 6.3 Catalent: Net Revenues, FY 2015-FY 2019 (USD Million)
Figure 6.4 Catalent: Service Portfolio
Figure 6.5 Cayman Chemical: Service Portfolio
Figure 6.6 Pillar5 Pharma: Service Portfolio
Figure 6.7 Sterling Pharmaceutical Services: Service Portfolio
Figure 7.1 FARMIGEA: Service Portfolio
Figure 7.2 Lomapharm: Service Portfolio
Figure 7.3 Medichem: Service Portfolio
Figure 7.4 Recipharm: Net Revenues, FY 2015-Q3 2019 (SEK Million)
Figure 7.5 Recipharm: Service Portfolio
Figure 7.6 Salvat: Service Portfolio
Figure 8.1 Akums: Service Portfolio
Figure 8.2 Bal Pharma: Net Revenues, FY 2015-FY 2019 (INR Million)
Figure 8.3 Bal Pharma: Service Portfolio
Figure 8.4 Entod Pharmaceuticals: Service Portfolio
Figure 8.5 Glenmark Pharmaceuticals: Service Portfolio
Figure 8.6 Indiana Ophthalmics: Service Portfolio
Figure 8.7 Sunways India: Service Portfolio
Figure 9.1 Clinical Trials: Distribution by Trial Recruitment Status
Figure 9.2 Clinical Trials: Cumulative Distribution by Trial Registration Year, Pre-2010-Q3 2019
Figure 9.3 Clinical Trials: Geographical Distribution by Number of Clinical Trials
Figure 9.4 Clinical Trials: Percentage Increase in Number of Trials, Pre- and Post-2010
Figure 9.5 Clinical Trials: Distribution by Trial Registration Year and Geography, Pre-2010-2018
Figure 9.6 Clinical Trials: Geographical Distribution by Enrolled Patient Population
Figure 9.7 Clinical Trials: Cumulative Distribution by Enrolled Patient Population and Trial Registration Year, Pre-2010-Q3 2019
Figure 9.8 Clinical Trials: Distribution by Phase of Development
Figure 9.9 Clinical Trials: Distribution by Trial Recruitment Status and Registration Year, Pre-2010-Q3 2019
Figure 9.10 Clinical Trials: Geographical Distribution by Trial Recruitment Status and Registration Year, Pre- and Post-2010
Figure 9.11 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 9.12 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 9.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 9.14 Clinical Trials: Distribution by Type of Intervention
Figure 9.15 Clinical Trials: Distribution by Type of Intervention and Trial Registration Year, 2010-2018
Figure 9.16 Clinical Trials: Popular Keywords
Figure 9.17 Popular Indications: Distribution by Number of Registered Trials
Figure 9.18 Clinical Trials: Distribution by Popular Indications and Trial Registration Year, 2010-2018
Figure 9.19 Clinical Trials: Distribution by Popular Indications and Type of Trial Sponsor
Figure 9.20 Clinical Trials: Distribution by Most Active Industry Players and Trial Registration Year, 2013-2018
Figure 9.21 Clinical Trials: Benchmarking by Number of Trials across Popular Indications
Figure 10.1 Ophthalmic API Contract Manufacturers: Overall Production Capacity (Million Liters)
Figure 10.2 Ophthalmic API Production Capacity: Distribution by Geography (Million Liters)
Figure 10.3 Ophthalmic API Production Capacity in North America (Million Liters)
Figure 10.4 Ophthalmic API Production Capacity in Europe (Million Liters)
Figure 10.5 Ophthalmic API Production Capacity in Asia-Pacific (Million Liters)
Figure 10.6 Ophthalmic API Production Capacity: Distribution by Scale of Operation (Million Liters)
Figure 10.7 Lab Scale Ophthalmic API Production Capacity (Million Liters)
Figure 10.8 Clinical Scale Ophthalmic API Production Capacity (Million Liters)
Figure 10.9 Commercial Scale Ophthalmic API Production Capacity (Million Liters)
Figure 10.10 Ophthalmic API Production Capacity: Distribution by Company Size (Million Liters)
Figure 10.11 Ophthalmic API Production Capacity of Small-sized Companies (Million Liters)
Figure 10.12 Ophthalmic API Production Capacity of Mid-sized Companies (Million Liters)
Figure 10.13 Ophthalmic API Production Capacity of Large-sized Companies (Million Liters)
Figure 10.14 Ophthalmic Drug FDF Contract Manufacturers: Overall Production Capacity (Million Liters)
Figure 10.15 Ophthalmic Drug FDF Production Capacity: Distribution by Geography (Million Liters)
Figure 10.16 Ophthalmic Drug FDF Production Capacity in North America (Million Liters)
Figure 10.17 Ophthalmic Drug FDF Production Capacity in Europe (Million Liters)
Figure 10.18 Ophthalmic Drug FDF Production Capacity in Asia-Pacific (Million Liters)
Figure 10.19 Ophthalmic Drug FDF Production Capacity: Distribution by Scale of Operation (Million Liters)
Figure 10.20 Lab Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
Figure 10.21 Clinical Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
Figure 10.22 Commercial Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
Figure 10.23 Ophthalmic Drug FDF Production Capacity: Distribution by Company Size (Million Liters)
Figure 10.24 Ophthalmic Drug FDF Production Capacity of Small-sized Companies (Million Liters)
Figure 10.25 Ophthalmic Drug FDF Production Capacity of Mid-sized Companies (Million Liters)
Figure 10.26 Ophthalmic Drug FDF Production Capacity of Large-sized Companies (Million Liters)
Figure 10.27 Ophthalmic Drug FDF Production Capacity: Distribution by Type of Primary Packaging (Million Liters)
Figure 10.28 Ophthalmic Drug FDF Production Capacity of Ampoules / Vials (Million Liters)
Figure 10.29 Ophthalmic Drug FDF Production Capacity of Glass / Plastic Bottles (Million Liters)
Figure 10.30 Ophthalmic Drug FDF Production Capacity of Ointment Tubes (Million Liters)
Figure 10.31 Ophthalmic Drug FDF Contract Manufacturers: Overall Production Capacity (Million Units)
Figure 10.32 Ophthalmic Drug FDF Production Capacity: Distribution by Geography (Million Units)
Figure 10.33 Ophthalmic Drug FDF Production Capacity in North America (Million Units)
Figure 10.34 Ophthalmic Drug FDF Production Capacity in Europe (Million Units)
Figure 10.35 Ophthalmic Drug FDF Production Capacity in Asia-Pacific (Million Units)
Figure 10.36 Ophthalmic Drug FDF Capacity: Distribution by Scale of Operation (Million Units)
Figure 10.37 Lab Scale Ophthalmic Drug FDF Production Capacity (Million Units)
Figure 10.38 Clinical Scale Ophthalmic Drug FDF Production Capacity (Million Units)
Figure 10.39 Commercial Scale Ophthalmic Drug FDF Production Capacity (Million Units)
Figure 10.40 Ophthalmic Drug FDF Capacity: Distribution by Company Size (Million Units)
Figure 10.41 Ophthalmic Drug FDF Production Capacity of Small-sized Companies (Million Units)
Figure 10.42 Ophthalmic Drug FDF Production Capacity of Mid-sized Companies (Million Units)
Figure 10.43 Ophthalmic Drug FDF Production Capacity of Large-sized Companies (Million Units)
Figure 10.44 Ophthalmic Drug FDF Capacity: Distribution by Type of Primary Packaging (Million Units)
Figure 10.45 Ophthalmic Drug FDF Production Capacity of Ampoules / Vials (Million Units)
Figure 10.46 Ophthalmic Drug FDF Production Capacity of Glass / Plastic Bottles (Million Units)
Figure 10.47 Ophthalmic Drug FDF Production Capacity of Ointment Tubes (Million Units)
Figure 11.1 Overall Commercial Demand for Ophthalmic API Contract Manufacturing (Million Liters)
Figure 11.2 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Geography (Million Liters)
Figure 11.3 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Figure 11.4 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Target Indication (Million Liters)
Figure 11.5 Overall Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing (Million Liters)
Figure 11.6 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Geography (Million Liters)
Figure 11.7 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Figure 11.8 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Target Indication (Million Liters)
Figure 11.9 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Type of Primary Packaging (Million Liters)
Figure 11.10 Overall Clinical Demand for Ophthalmic API Contract Manufacturing (Million Liters)
Figure 11.11 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Geography (Million Liters)
Figure 11.12 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Figure 11.13 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Target Indication (Million Liters)
Figure 11.14 Overall Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing (Million Liters)
Figure 11.15 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Geography (Million Liters)
Figure 11.16 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Figure 11.17 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Target Indication (Million Liters)
Figure 11.18 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Primary Packaging (Million Liters)
Figure 11.19 Overall Ophthalmic Drugs Contract Manufacturing: Demand and Supply
Figure 12.1 Overall Ophthalmic Drugs Contract Manufacturing Market, 2020-2030 (USD Billion)
Figure 12.2 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Product (USD Billion)
Figure 12.3 Ophthalmic API Contract Manufacturing Market, 2020-2030 (USD Billion)
Figure 12.4 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030 (USD Billion)
Figure 12.5 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of FDF Manufactured (USD Billion)
Figure 12.6 Ophthalmic Drugs Contract Manufacturing Market for Solids, 2020-2030 (USD Billion)
Figure 12.7 Ophthalmic Drugs Contract Manufacturing Market for Semi-solids, 2020-2030 (USD Billion)
Figure 12.8 Ophthalmic Drugs Contract Manufacturing Market for Liquids / Suspensions, 2020-2030 (USD Billion)
Figure 12.9 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of Primary Packaging (USD Billion)
Figure 12.10 Ophthalmic Drugs Contract Manufacturing Market for Ampoules / Vials, 2020-2030 (USD Billion)
Figure 12.11 Ophthalmic Drugs Contract Manufacturing Market for Glass / Plastic Bottles, 2020-2030 (USD Billion)
Figure 12.12 Ophthalmic Drugs Contract Manufacturing Market for Ointment Tubes, 2020-2030 (USD Billion)
Figure 12.13 Ophthalmic Drugs Contract Manufacturing Market for Blister Packing, 2020-2030 (USD Billion)
Figure 12.14 Ophthalmic Drugs Contract Manufacturing Market for Other Packaging Forms, 2020-2030 (USD Billion)
Figure 12.15 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Target Disease Indication (USD Billion)
Figure 12.16 Ophthalmic Drugs Contract Manufacturing Market for Age-related Macular Degeneration, 2020-2030 (USD Billion)
Figure 12.17 Ophthalmic Drugs Contract Manufacturing Market for Dry Eye, 2020-2030 (USD Billion)
Figure 12.18 Ophthalmic Drugs Contract Manufacturing Market for Glaucoma, 2020-2030 (USD Billion)
Figure 12.19 Ophthalmic Drugs Contract Manufacturing Market for Uveitis, 2020-2030 (USD Billion)
Figure 12.20 Ophthalmic Drugs Contract Manufacturing Market for Other Eye Disorders, 2020-2030 (USD Billion)
Figure 12.21 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Figure 12.22 Ophthalmic Drugs Contract Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030 (USD Billion)
Figure 12.23 Ophthalmic Drugs Contract Manufacturing Market for Commercial Scale Operations, 2020-2030 (USD Billion)
Figure 12.24 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Company Size (USD Billion)
Figure 12.25 Ophthalmic Drugs Contract Manufacturing Market for Small-sized Companies, 2020-2030 (USD Billion)
Figure 12.26 Ophthalmic Drugs Contract Manufacturing Market for Mid-sized Companies, 2020-2030 (USD Billion)
Figure 12.27 Ophthalmic Drugs Contract Manufacturing Market for Large-sized Companies, 2020-2030 (USD Billion)
Figure 12.28 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Geographical Regions (USD Billion)
Figure 12.29 Ophthalmic Drugs Contract Manufacturing Market in North America, 2020-2030 (USD Billion)
Figure 12.30 Ophthalmic Drugs Contract Manufacturing Market in the US, 2020-2030 (USD Billion)
Figure 12.31 Ophthalmic Drugs Contract Manufacturing Market in Canada, 2020-2030 (USD Billion)
Figure 12.32 Ophthalmic Drugs Contract Manufacturing Market in Mexico, 2020-2030 (USD Billion)
Figure 12.33 Ophthalmic Drugs Contract Manufacturing Market in Europe, 2020-2030 (USD Billion)
Figure 12.34 Ophthalmic Drugs Contract Manufacturing Market in the UK, 2020-2030 (USD Billion)
Figure 12.35 Ophthalmic Drugs Contract Manufacturing Market in Germany, 2020-2030 (USD Billion)
Figure 12.36 Ophthalmic Drugs Contract Manufacturing Market in France, 2020-2030 (USD Billion)
Figure 12.37 Ophthalmic Drugs Contract Manufacturing Market in Spain, 2020-2030 (USD Billion)
Figure 12.38 Ophthalmic Drugs Contract Manufacturing Market in Italy, 2020-2030 (USD Billion)
Figure 12.39 Ophthalmic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030 (USD Billion)
Figure 12.40 Ophthalmic Drugs Contract Manufacturing Market in Asia-Pacific, 2020-2030 (USD Billion)
Figure 12.41 Ophthalmic Drugs Contract Manufacturing Market in India, 2020-2030 (USD Billion)
Figure 12.42 Ophthalmic Drugs Contract Manufacturing Market in China, 2020-2030 (USD Billion)
Figure 12.43 Ophthalmic Drugs Contract Manufacturing Market in Japan, 2020-2030 (USD Billion)
Figure 12.44 Ophthalmic Drugs Contract Manufacturing Market in Australia, 2020-2030 (USD Billion)
Figure 12.45 Ophthalmic Drugs Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.1 Small Molecule Drugs and Biologics: Historical Trend of FDA Approval, 2010-Q3 2019
Figure 13.2 Comparison of Key Characteristics of Small Molecules and Biologics
Figure 13.3 Comparison of Manufacturing Processes of Small Molecules and Biologics
Figure 14.1 Ophthalmic Drugs Contract Manufacturing: SWOT Analysis
Figure 14.2. Comparison of SWOT Factors: Harvey Ball Analysis
Figure 15.1 Survey Insights: Overview of Respondents
Figure 15.2 Survey Insights: Distribution by Type of Organization
Figure 15.3 Survey Insights: Distribution by Location of Organization
Figure 15.4 Survey Insights: Distribution by Seniority Level
Figure 15.5 Survey Insights: Distribution by Type of Product
Figure 15.6 Survey Insights: Distribution by Type of Primary Packaging
Figure 15.7 Survey Insights: Distribution by Scale of Operation
Figure 15.8 Survey Insights: Distribution by Location of Manufacturing Facilities
Figure 15.9 Survey Insights: Distribution by Regulatory Accreditations / Certifications of Manufacturing Facilities
Figure 15.10 Survey Insights: Distribution by Extent of Outsourcing

List Of  Tables 

Table 4.1 Ophthalmic Drug Contract Manufacturers: List of Industry Players
Table 4.2 Ophthalmic Drug Contract Manufacturers: Information on Location of FDF Manufacturing Facilities
Table 4.3 Ophthalmic Drug Contract Manufacturers: Information on Location of API Manufacturing Facilities
Table 4.4 Ophthalmic Drug Contract Manufacturers: Information on Type of FDF Manufactured and Type of Primary Packaging
Table 4.5 Ophthalmic Drug Contract Manufacturers: Information on Type of Service(s) Offered
Table 4.6 Ophthalmic Drug Contract Manufacturers: Information on Regulatory Accreditations / Certifications
Table 6.1 Akorn: Key Highlights
Table 6.2 Akorn: Manufacturing Capabilities
Table 6.3 Akorn: Recent Developments and Future Outlook
Table 6.4 Catalent: Key Highlights
Table 6.5 Catalent: Recent Developments and Future Outlook
Table 6.6 Cayman Chemical: Key Highlights
Table 6.7 Cayman Chemical: Manufacturing Capabilities
Table 6.8 Cayman Chemical: Recent Developments and Future Outlook
Table 6.9 Pillar5 Pharma: Key Highlights
Table 6.10 Pillar5 Pharma: Recent Developments and Future Outlook
Table 6.11 Sterling Pharmaceutical Services: Key Highlights
Table 6.12 Sterling Pharmaceutical Services: Recent Developments and Future Outlook
Table 7.1 FARMIGEA: Key Highlights
Table 7.2 FARMIGEA: Manufacturing Capabilities
Table 7.3 FARMIGEA: Recent Developments and Future Outlook
Table 7.4 Lomapharm: Key Highlights
Table 7.5 Lomapharm: Recent Developments and Future Outlook
Table 7.6 Medichem: Key Highlights
Table 7.7 Medichem: Manufacturing Capabilities
Table 7.8 Medichem: Manufacturing Locations
Table 7.9 Medichem: Recent Developments and Future Outlook
Table 7.10 Recipharm: Key Highlights
Table 7.11 Recipharm: Manufacturing Locations
Table 7.12 Recipharm: Recent Developments and Future Outlook
Table 7.13 Salvat: Key Highlights
Table 7.14 Salvat: Manufacturing Capabilities
Table 7.15 Salvat: Recent Developments and Future Outlook
Table 8.1 Akums: Key Highlights
Table 8.2 Akums: Recent Developments and Future Outlook
Table 8.3 Bal Pharma: Key Highlights
Table 8.4 Bal Pharma: Recent Developments and Future Outlook
Table 8.5 Entod Pharmaceuticals: Key Highlights
Table 8.6 Entod Pharmaceuticals: Manufacturing Capabilities
Table 8.7 Entod Pharmaceuticals: Recent Developments and Future Outlook
Table 8.8 Glenmark Pharmaceuticals: Key Highlights
Table 8.9 Glenmark Pharmaceuticals: Recent Developments and Future Outlook
Table 8.10 Indiana Ophthalmics: Key Highlights
Table 8.11 Indiana Ophthalmics: Recent Developments and Future Outlook
Table 8.12 Sunways India: Key Highlights
Table 8.13 Sunways India: Recent Developments and Future Outlook
Table 10.1 Ophthalmic API Production Capacity (Million Liters): Average Capacity by Geography (Sample Data Set)
Table 10.2 Ophthalmic API Production Capacity (Million Liters): Average Capacity by Scale of Operation (Sample Data Set)
Table 10.3 Ophthalmic API Production Capacity (Million Liters): Average Capacity by Company Size (Sample Data Set)
Table 10.4 Ophthalmic Drug FDF Production Capacity (Million Liters): Average Capacity by Geography (Sample Data Set)
Table 10.5 Ophthalmic Drug FDF Production Capacity (Million Liters): Average Capacity by Scale of Operation (Sample Data Set)
Table 10.6 Ophthalmic Drug FDF Production Capacity (Million Liters): Average Capacity by Company Size (Sample Data Set)
Table 10.7 Ophthalmic Drug FDF Production Capacity (Million Liters): Average Capacity by Type of Primary Packaging (Sample Data Set)
Table 10.8 Ophthalmic Drug FDF Production Capacity (Million Units): Average Capacity by Geography (Sample Data Set)
Table 10.9 Ophthalmic Drug FDF Production Capacity (Million Units): Average Capacity by Scale of Operation (Sample Data Set)
Table 10.10 Ophthalmic Drug FDF Production Capacity (Million Units): Average Capacity by Company Size (Sample Data Set)
Table 10.11 Ophthalmic Drug FDF Production Capacity (Million Units): Average Capacity by Type of Primary Packaging (Sample Data Set)
Table 13.1 Strengths and Weaknesses of Small Molecules and Biologics
Table 13.2 Comparison of Development Characteristics of Small Molecules and Biologics
Table 15.1 Survey Insights: Overview of Respondents
Table 15.2 Survey Insights: Seniority Level of Respondents
Table 15.3 Survey Insights: Type of Product
Table 15.4 Survey Insights: Type of Primary Packaging
Table 15.5 Survey Insights: Scale of Operation
Table 15.6 Survey Insights: Manufacturing Capacity
Table 15.7 Survey Insights: Number and Location of Manufacturing Facilities
Table 15.8 Survey Insights: Regulatory Accreditations / Certifications of Manufacturing Facilities
Table 15.9 Survey Insights: Extent of Outsourcing
Table 15.10 Survey Insights: Current Market Opportunity (USD Billion)
Table 16.1 Selvok Pharmaceutical: Key Highlights
Table 16.2 Caplin Point Laboratories: Key Highlights
Table 16.3 Phytex Australia: Key Highlights
Table 16.4 Gland Pharma: Key Highlights
Table 18.1 Ophthalmic Medical Device Contract Manufacturers: List of Industry Players
Table 18.2 Ophthalmic Medical Device Contract Manufacturers: Information on Type of Service(s) Offered and Scale of Operation
Table 18.3 Ophthalmic Medical Device Contract Manufacturers: Information on Additional Service(s) Offered
Table 18.4 Ophthalmic Medical Device Contract Manufacturers: Information on Location of Manufacturing Facilities
Table 18.5 Ophthalmic Medical Device Contract Manufacturers: Information on Device Class and Regulatory Accreditations / Certifications
Table 19.1 Estimates on the Visually Impaired Population (US), 2019, 2030 and 2050 (in Millions)
Table 19.2 Ophthalmic Drug Contract Manufacturers: Distribution by Year of Establishment
Table 19.3 Ophthalmic Drug Contract Manufacturers: Distribution by Company Size
Table 19.4 Ophthalmic Drug Contract Manufacturers: Distribution by Scale of Operation
Table 19.5 Ophthalmic Drug Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Table 19.6 Ophthalmic Drug Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Table 19.7 Ophthalmic Drug Contract Manufacturers: Distribution by Location of FDF Manufacturing Facilities (Region-Wise)
Table 19.8 Ophthalmic Drug Contract Manufacturers: Distribution by Location of FDF Manufacturing Facilities (Country-Wise)
Table 19.9 Ophthalmic Drug Contract Manufacturers: Distribution by Location of API Manufacturing Facilities (Region-Wise)
Table 19.10 Ophthalmic Drug Contract Manufacturers: Distribution by Location of API Manufacturing Facilities (Country-Wise)
Table 19.11 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Product
Table 19.12 Ophthalmic Drug Contract Manufacturers: Distribution by Type of FDF Manufactured
Table 19.13 Ophthalmic Drug Contract Manufacturers: Distribution by Type of FDF Manufactured and Company Size
Table 19.14 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Primary Packaging
Table 19.15 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Service(s) Offered
Table 19.16 Ophthalmic Drug Contract Manufacturers: Distribution by Regulatory Accreditations / Certifications
Table 19.17 Akorn: Net Revenues, FY 2015-Q3 2019 (USD Million)
Table 19.18 Catalent: Net Revenues, FY 2015-FY 2019 (USD Million)
Table 19.19 Recipharm: Net Revenues, FY 2015-Q3 2019 (SEK Million)
Table 19.20 Bal Pharma: Net Revenues, FY 2015-FY 2019 (INR Million)
Table 19.21 Clinical Trials: Distribution by Trial Recruitment Status
Table 19.22 Clinical Trials: Cumulative Distribution by Trial Registration Year, Pre-2010-Q3 2019
Table 19.23 Clinical Trials: Geographical Distribution by Number of Clinical Trials
Table 19.24 Clinical Trials: Percentage Increase in Number of Trials, Pre- and Post-2010
Table 19.25 Clinical Trials: Distribution by Trial Registration Year and Geography, Pre-2010-2018
Table 19.26 Clinical Trials: Geographical Distribution by Enrolled Patient Population
Table 19.27 Clinical Trials: Cumulative Distribution by Enrolled Patient Population and Trial Registration Year, Pre-2010-Q3 2019
Table 19.28 Clinical Trials: Distribution by Phase of Development
Table 19.29 Clinical Trials: Distribution by Trial Recruitment Status and Registration Year, Pre-2010-Q3 2019
Table 19.30 Clinical Trials: Geographical Distribution by Trial Recruitment Status and Registration Year, Pre- and Post-2010
Table 19.31 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 19.32 Most Active Industry Players: Distribution by Number of Registered Trials
Table 19.33 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 19.34 Clinical Trials: Distribution by Type of Intervention
Table 19.35 Clinical Trials: Distribution by Type of Intervention and Trial Registration Year, 2010-2018
Table 19.36 Popular Indications: Distribution by Number of Registered Trials
Table 19.37 Clinical Trials: Distribution by Popular Indications and Trial Registration Year, 2010-2018
Table 19.38 Clinical Trials: Distribution by Popular Indications and Type of Trial Sponsor
Table 19.39 Clinical Trials: Distribution by Most Active Industry Players and Trial Registration Year, 2013-2018
Table 19.40 Clinical Trials: Benchmarking by Number of Trials across Popular Indications
Table 19.41 Ophthalmic API Contract Manufacturers: Overall Production Capacity (Million Liters)
Table 19.42 Ophthalmic API Production Capacity: Distribution by Geography (Million Liters)
Table 19.43 Ophthalmic API Production Capacity in North America (Million Liters)
Table 19.44 Ophthalmic API Production Capacity in Europe (Million Liters)
Table 19.45 Ophthalmic API Production Capacity in Asia-Pacific (Million Liters)
Table 19.46 Ophthalmic API Production Capacity: Distribution by Scale of Operation (Million Liters)
Table 19.47 Lab Scale Ophthalmic API Production Capacity (Million Liters)
Table 19.48 Clinical Scale Ophthalmic API Production Capacity (Million Liters)
Table 19.49 Commercial Scale Ophthalmic API Production Capacity (Million Liters)
Table 19.50 Ophthalmic API Production Capacity: Distribution by Company Size (Million Liters)
Table 19.51 Ophthalmic API Production Capacity of Small-sized Companies (Million Liters)
Table 19.52 Ophthalmic API Production Capacity of Mid-sized Companies (Million Liters)
Table 19.53 Ophthalmic API Production Capacity of Large-sized Companies (Million Liters)
Table 19.54 Ophthalmic Drug FDF Contract Manufacturers: Overall Production Capacity (Million Liters)
Table 19.55 Ophthalmic Drug FDF Production Capacity: Distribution by Geography (Million Liters)
Table 19.56 Ophthalmic Drug FDF Production Capacity in North America (Million Liters)
Table 19.57 Ophthalmic Drug FDF Production Capacity in Europe (Million Liters)
Table 19.58 Ophthalmic Drug FDF Production Capacity in Asia-Pacific (Million Liters)
Table 19.59 Ophthalmic Drug FDF Production Capacity: Distribution by Scale of Operation (Million Liters)
Table 19.60 Lab Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
Table 19.61 Clinical Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
Table 19.62 Commercial Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
Table 19.63 Ophthalmic Drug FDF Production Capacity: Distribution by Company Size (Million Liters)
Table 19.64 Ophthalmic Drug FDF Production Capacity of Small-sized Companies (Million Liters)
Table 19.65 Ophthalmic Drug FDF Production Capacity of Mid-sized Companies (Million Liters)
Table 19.66 Ophthalmic Drug FDF Production Capacity of Large-sized Companies (Million Liters)
Table 19.67 Ophthalmic Drug FDF Production Capacity: Distribution by Type of Primary Packaging (Million Liters)
Table 19.68 Ophthalmic Drug FDF Production Capacity of Ampoules / Vials (Million Liters)
Table 19.69 Ophthalmic Drug FDF Production Capacity of Glass / Plastic Bottles (Million Liters)
Table 19.70 Ophthalmic Drug FDF Production Capacity of Ointment Tubes (Million Liters)
Table 19.71 Ophthalmic Drug FDF Contract Manufacturers: Overall Production Capacity (Million Units)
Table 19.72 Ophthalmic Drug FDF Production Capacity: Distribution by Geography (Million Units)
Table 19.73 Ophthalmic Drug FDF Production Capacity in North America (Million Units)
Table 19.74 Ophthalmic Drug FDF Production Capacity in Europe (Million Units)
Table 19.75 Ophthalmic Drug FDF Production Capacity in Asia-Pacific (Million Units)
Table 19.76 Ophthalmic Drug FDF Capacity: Distribution by Scale of Operation (Million Units)
Table 19.77 Lab Scale Ophthalmic Drug FDF Production Capacity (Million Units)
Table 19.78 Clinical Scale Ophthalmic Drug FDF Production Capacity (Million Units)
Table 19.79 Commercial Scale Ophthalmic Drug FDF Production Capacity (Million Units)
Table 19.80 Ophthalmic Drug FDF Capacity: Distribution by Company Size (Million Units)
Table 19.81 Ophthalmic Drug FDF Production Capacity of Small-sized Companies (Million Units)
Table 19.82 Ophthalmic Drug FDF Production Capacity of Mid-sized Companies (Million Units)
Table 19.83 Ophthalmic Drug FDF Production Capacity of Large-sized Companies (Million Units)
Table 19.84 Ophthalmic Drug FDF Capacity: Distribution by Type of Primary Packaging (Million Units)
Table 19.85 Ophthalmic Drug FDF Production Capacity of Ampoules / Vials (Million Units)
Table 19.86 Ophthalmic Drug FDF Production Capacity of Glass / Plastic Bottles (Million Units)
Table 19.87 Ophthalmic Drug FDF Production Capacity of Ointment Tubes (Million Units)
Table 19.88 Overall Commercial Demand for Ophthalmic API Contract Manufacturing (Million Liters)
Table 19.89 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Geography (Million Liters)
Table 19.90 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Table 19.91 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Target Indication (Million Liters)
Table 19.92 Overall Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing (Million Liters)
Table 19.93 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Geography (Million Liters)
Table 19.94 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Table 19.95 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Target Indication (Million Liters)
Table 19.96 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Type of Primary Packaging (Million Liters)
Table 19.97 Overall Clinical Demand for Ophthalmic API Contract Manufacturing (Million Liters)
Table 19.98 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Geography (Million Liters)
Table 19.99 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Table 19.100 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Target Indication (Million Liters)
Table 19.101 Overall Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing (Million Liters)
Table 19.102 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Geography (Million Liters)
Table 19.103 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Table 19.104 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Target Indication (Million Liters)
Table 19.105 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Primary Packaging (Million Liters)
Table 19.106 Overall Ophthalmic Drugs Contract Manufacturing: Demand and Supply
Table 19.107 Overall Ophthalmic Drugs Contract Manufacturing Market, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.108 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Product, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.109 Ophthalmic API Contract Manufacturing Market, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.110 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.111 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of FDF Manufactured, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.112 Ophthalmic Drugs Contract Manufacturing Market for Solids, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.113 Ophthalmic Drugs Contract Manufacturing Market for Semi-solids, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.114 Ophthalmic Drugs Contract Manufacturing Market for Liquids / Suspensions, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.115 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of Primary Packaging, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.116 Ophthalmic Drugs Contract Manufacturing Market for Ampoules / Vials, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.117 Ophthalmic Drugs Contract Manufacturing Market for Glass / Plastic Bottles, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.118 Ophthalmic Drugs Contract Manufacturing Market for Ointment Tubes, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.119 Ophthalmic Drugs Contract Manufacturing Market for Blister Packing, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.120 Ophthalmic Drugs Contract Manufacturing Market for Other Packaging Forms, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.121 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Target Disease Indication, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.122 Ophthalmic Drugs Contract Manufacturing Market for Age-related Macular Degeneration, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.123 Ophthalmic Drugs Contract Manufacturing Market for Dry Eye, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.124 Ophthalmic Drugs Contract Manufacturing Market for Glaucoma, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.125 Ophthalmic Drugs Contract Manufacturing Market for Uveitis, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.126 Ophthalmic Drugs Contract Manufacturing Market for Other Eye Disorders, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.127 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.128 Ophthalmic Drugs Contract Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.129 Ophthalmic Drugs Contract Manufacturing Market for Commercial Scale Operations, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.130 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Company Size, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.131 Ophthalmic Drugs Contract Manufacturing Market for Small-sized Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.132 Ophthalmic Drugs Contract Manufacturing Market for Mid-sized Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.133 Ophthalmic Drugs Contract Manufacturing Market for Large-sized Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.134 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Geographical Regions, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.135 Ophthalmic Drugs Contract Manufacturing Market in North America, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.136 Ophthalmic Drugs Contract Manufacturing Market in the US, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.137 Ophthalmic Drugs Contract Manufacturing Market in Canada, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.138 Ophthalmic Drugs Contract Manufacturing Market in Mexico, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.139 Ophthalmic Drugs Contract Manufacturing Market in Europe, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.140 Ophthalmic Drugs Contract Manufacturing Market in the UK, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.141 Ophthalmic Drugs Contract Manufacturing Market in Germany, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.142 Ophthalmic Drugs Contract Manufacturing Market in France, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.143 Ophthalmic Drugs Contract Manufacturing Market in Spain, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.144 Ophthalmic Drugs Contract Manufacturing Market in Italy, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.145 Ophthalmic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.146 Ophthalmic Drugs Contract Manufacturing Market in Asia-Pacific, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.147 Ophthalmic Drugs Contract Manufacturing Market in India, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.148 Ophthalmic Drugs Contract Manufacturing Market in China, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.149 Ophthalmic Drugs Contract Manufacturing Market in Japan, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.150 Ophthalmic Drugs Contract Manufacturing Market in Australia, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.151 Ophthalmic Drugs Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.152 Small Molecule Drugs and Biologics: Historical Trend of FDA Approval, 2010-Q3 2019
Table 19.153 Survey Insights: Distribution by Type of Organization
Table 19.154 Survey Insights: Distribution by Location of Organization
Table 19.155 Survey Insights: Distribution by Seniority Level
Table 19.156 Survey Insights: Distribution by Type of Product
Table 19.157 Survey Insights: Distribution by Type of Primary Packaging
Table 19.158 Survey Insights: Distribution by Scale of Operation
Table 19.159 Survey Insights: Distribution by Location of Manufacturing Facilities
Table 19.160 Survey Insights: Distribution by Regulatory Accreditations / Certifications of Manufacturing Facilities
Table 19.161 Survey Insights: Distribution by Extent of Outsourcing

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. A. S. Joshi & Company
  2. Aarti Industries
  3. Abbott Medical Optics
  4. AccuMED 
  5. Actiza Pharmaceutical
  6. Admac Formulations
  7. Aerie Pharmaceuticals
  8. AGC Biologics
  9. Aishwarya Lifescience
  10. Akorn
  11. Akums
  12. Alcon 
  13. Alembic Pharmaceuticals
  14. Allergan
  15. Amanta Healthcare
  16. Ambica Pharma Sales
  17. AMETEK Engineered Medical Components
  18. Amman Pharmaceutical Industries
  19. AMRI
  20. ANI Pharmaceuticals 
  21. Apex Pharmaceuticals
  22. Apicore US
  23. Arvincare
  24. Ashford Pharmaceutical Laboratories
  25. Aspen Pharmacare
  26. Assiut University
  27. Astellas Pharma
  28. Aster Pharma
  29. AstraZeneca
  30. Atrion Medical
  31. Aurobindo Pharma
  32. Avalign Technologies
  33. Axa Parenterals
  34. Bachem
  35. BAL Pharma
  36. Bausch & Lomb 
  37. Bayer
  38. Baylor College of Medicine
  39. Beijing Second Pharmaceutical
  40. Bennet Pharmaceuticals
  41. BePharBel
  42. Beximco Pharmaceuticals
  43. Binex
  44. Biocon
  45. Bioglan
  46. Biomol
  47. Biotech Vision Care
  48. Boehringer Ingelheim
  49. Bolivac Pharmaceutical 
  50. Bonarum Pharma
  51. Brassica Pharma
  52. Bristol-Myers Squibb
  53. C&J Industries
  54. Cadence
  55. Cadila Pharmaceuticals
  56. Cairo University
  57. Cambrex
  58. Caplin Point Laboratories
  59. Capsugel
  60. Captab Biotec
  61. Carclo
  62. Catalent
  63. Cayman Chemical
  64. CCM Pharmaceuticals
  65. Centaur Pharmaceuticals
  66. Center for Drug Evaluation and Research 
  67. Century Pharmaceuticals
  68. Ceutical Labs
  69. Chang Gung Memorial Hospital
  70. Charité University
  71. ChemCon
  72. Chemigran
  73. Chifeng Arker Pharmaceutical Technology
  74. Chirogate International 
  75. Chongqing Huapont Pharmaceutical 
  76. Chromo Laboratories India 
  77. Ciron Drugs
  78. CiVentiChem
  79. Coastline International
  80. COC Farmaceutici 
  81. Columbia University
  82. Combino Pharm
  83. Concord Drugs
  84. Consort Medical
  85. CooperVision
  86. CoreRx
  87. CTX Lifesciences
  88. Daicel 
  89. Deepcare Health 
  90. Delorbis 
  91. Delpharm
  92. Denator
  93. Dermopartners 
  94. Deva Holding
  95. DeviceLab
  96. Dhruv Life Sciences
  97. DM Pharma
  98. Doctor Pack
  99. Dompé 
  100. Donatelle
  101. Dr. Reddy’s Laboratories
  102. Duke University
  103. Eden Healthcare
  104. Edol Laboratory
  105. EL Laboratories
  106. Eminent Healthcare
  107. Emory University
  108. Enaltec Labs
  109. Entod Pharmaceuticals 
  110. Eskayef Pharmaceuticals
  111. Eurofins
  112. Euro-Med Laboratories
  113. EVCO Plastics
  114. Evergreen Research
  115. Evolet Healthcare
  116. Excella 
  117. Excelvision
  118. Exela Pharma Science
  119. EXODRUG
  120. Fabbrica Italiana Sintetici 
  121. FAMAR 
  122. Fantabulous Pharma
  123. Fareva
  124. Farmak
  125. Farmastur 2010
  126. FARMIGEA
  127. FDC
  128. Federal University of São Paulo
  129. Fermion
  130. Finecure Pharmaceuticals
  131. FineTech Pharmaceuticals
  132. Finnsusp
  133. Flagship Biotech International
  134. Flamma Group
  135. Fleming Laboratories 
  136. Flexan
  137. Forefront Medical Technology
  138. Freudenberg Medical
  139. FSUE Moscow Endocrine Plant
  140. Galentic Pharma
  141. Gedeon Richter 
  142. Genentech
  143. Gerresheimer
  144. Gland Pharma
  145. Glaukos
  146. GlaxoSmithKline
  147. Glenmark Pharmaceuticals
  148. Glochem Industries 
  149. Golden Drugs
  150. Grevis Pharmaceuticals
  151. Groupe SYNERLAB
  152. Grupo Farmasierra
  153. GTIMD 
  154. Guilin Pharmaceutical
  155. Handok
  156. Hangzhou Panyu Chemical 
  157. Hanuchem Laboratories
  158. Harmac Medical Products
  159. Health Biotech
  160. Healthcare Pharmaceuticals 
  161. Healthy Life Pharma 
  162. Hemofarm 
  163. Hetero Drugs
  164. Higgs Healthcare
  165. Hi-Tech Pharmacal 
  166. Hospices Civils de Lyon
  167. Hovione
  168. Hritik Chemicals
  169. Hubei Biocause Pharmaceutical
  170. Icahn School of Medicine at Mount Sinai
  171. IIFA Healthcare
  172. Indena
  173. Indiana Ophthalmics
  174. Indoco Remedies
  175. Ind-Swift 
  176. Instru-med
  177. Intas Pharmaceuticals 
  178. Inteprod 
  179. Interquim
  180. i-Pharmaceuticals
  181. I-Tek Medical Technologies
  182. ITL Group
  183. IVERIC bio   
  184. J B Chemicals & Pharmaceuticals
  185. Jabil
  186. Jaeb Center for Health Research
  187. Jawa pharmaceuticals
  188. JGL
  189. Jips Pharmaceuticals
  190. Johns Hopkins University
  191. Johnson & Johnson Vision Care
  192. JSC Tatchempharmpreparaty
  193. Jubilant HollisterStier
  194. Juniper Pharmaceuticals
  195. JunoPacific
  196. K C Pharmaceutical
  197. Kamat Pharmatech
  198. Katsura Chemical
  199. Kaysersberg Pharmaceuticals
  200. Kemwell
  201. Keshava Organics 
  202. Kilitch Drugs 
  203. Korten
  204. KP Pharmaceutical Technology
  205. Krishlar Pharma
  206. Kyowa Pharma Chemical 
  207. Labiana Group
  208. Laboratoires Thea
  209. Laboratorios Entema 
  210. Laboratorios Grin
  211. Laboratorios Lesvi
  212. Laboratorios Sophia
  213. Lacrivera 
  214. Laurus Synthesis 
  215. Lawson Health Research Institute
  216. Lenus LifeCare
  217. Lifekyor Pharmaceuticals
  218. Lifezen Healthcare
  219. Lighthouse Imaging
  220. LOBA Feinchemie 
  221. Logos Pharma
  222. Lohmann 
  223. Lomapharm
  224. Lubrizol
  225. Maastricht University Medical Center
  226. MacFarlan Smith
  227. Macter International
  228. Mahidol University
  229. Makcur Laboratories
  230. Martin & Brown Biosciences 
  231. Massachusetts Eye and Ear Infirmary
  232. Massachusetts General Hospital
  233. Maxnova Healthcare
  234. Maya Biotech
  235. Mayo Clinic
  236. MD Anderson Cancer Center
  237. Medbio 
  238. MEDFE INDIA
  239. Medical University of South Carolina
  240. Medical University of Vienna
  241. Medichem
  242. Medisearch Laboratories 
  243. Medpharm
  244. Memorial Sloan Kettering Cancer Center
  245. Mercator Pharmaceutical Solutions
  246. Merck
  247. Micro Labs
  248. Mission Laboratories
  249. MMG Healthcare
  250. Modern Medical Equipment
  251. Moorfields Eye Hospital 
  252. Morgen Helathcare
  253. Mylan 
  254. Nakoda Chemicals 
  255. National Cancer Institute 
  256. National Eye Institute
  257. National Heart, Lung, and Blood Institute
  258. National Institute of Allergy and Infectious Diseases
  259. National Institute of Child Health and Human Development
  260. National Institute of Diabetes and Digestive and Kidney Diseases
  261. National Institute of Mental Health
  262. National Institute of Neurological Disorders and Stroke
  263. National Institute on Aging
  264. National Institutes of Health
  265. National Institutes of Health Clinical Center
  266. National Taiwan University Hospital
  267. Neiss Labs
  268. Nemera 
  269. NEO Tech Medical
  270. Neuland Laboratories 
  271. NewGen BioPharma
  272. Nextar Chempharma Solutions
  273. NextPharma
  274. Nimbles Biotech
  275. Nitin Lifesciences
  276. Nitto Medic
  277. Nivon Specialities
  278. Northwestern University
  279. Novartis
  280. Nutragen Pharma
  281. Nvron Life Science
  282. NYU Langone Health
  283. Oceanic Pharmachem
  284. Ohio State University
  285. Olamic Pharma
  286. Olon
  287. Ora
  288. Oregon Health and Science University
  289. PannonPharma
  290. Park Pharmaceuticals
  291. Patheon
  292. Perrigo
  293. Pfizer
  294. Pfizer CentreOne
  295. Pharma Stulln
  296. Pharmaloop
  297. Pharmapack
  298. PHARMA-Q
  299. Pharmascience 
  300. Pharmer
  301. Phillips-Medisize
  302. Phoenix DeVentures 
  303. Phytex Australia
  304. Pillar5 Pharma
  305. Piramal Pharma Solutions
  306. PMC SMART Solutions
  307. Polpharma
  308. Polyzen
  309. PrimaPharma
  310. Prisha Healthcare
  311. Procos 
  312. Product Resources
  313. ProMed Pharma
  314. Proton Pharma
  315. Pushkar Pharma
  316. Qilu Pharmaceutical
  317. Qualiphar-Gifrer
  318. Qualitron Bio Medica
  319. Quality Tech Services
  320. Qualtra Pharmaceuticals
  321. Radico Remedies
  322. RAFARM
  323. Recipharm
  324. Red Star Contract Manufacturing
  325. REDWING Pharma
  326. Regeneron Pharmaceuticals
  327. Remington Pharmaceuticals
  328. Ritedose
  329. Riverside Medical Packaging
  330. Roche
  331. Röchling Medical
  332. Rohto Pharmaceuticals
  333. Rompharm
  334. Rubicon Research
  335. Rusan Pharma
  336. Salvat
  337. Salvus Pharma
  338. Samsung Medical Center
  339. Sanbio
  340. SANOCHEMIA Pharmazeutika
  341. Sanofi
  342. Santen
  343. Saphnix Lifesciences
  344. Saraca Solutions
  345. Sarvodaya Drugs & Pharmaceuticals
  346. SCD Pharmaceuticals
  347. ScinoPharm Taiwan
  348. Second Source Medical
  349. Selvok Pharmaceutical
  350. Sensimed
  351. Sentiss Pharma
  352. Seoul National University Hospital
  353. Shahid Beheshti University of Medical Sciences
  354. Shandong Xinhua Pharmaceutical 
  355. Sheba Medical Center
  356. Shenzhen Haorui Industrial
  357. Shilpa Medicare 
  358. Shire
  359. SHL Group
  360. Siegfried
  361. Singapore National Eye Centre
  362. Sinphar Pharmaceutical
  363. Sion Healthcare
  364. Smruthi Organics
  365. Societa Italiana Medicinali Scandicci
  366. Sofarimex
  367. Softigel
  368. Solitaire Pharmacia
  369. SOVEREIGN PHARMA
  370. Sovrin Plastics
  371. Spark Therapeutics
  372. Sparton
  373. Spectrum Plastics Group
  374. Square Pharmaceuticals 
  375. Sricure Herbs 
  376. SRS Pharmaceutical 
  377. Stanford University
  378. StarFish Medical
  379. Stellartech 
  380. Sterling Pharmaceutical Services
  381. Stevanato Group 
  382. Strategix Medical Solutions
  383. Sun Yat-sen University
  384. Sungwoo Life Sciences 
  385. Sunways
  386. Swiss Pharma 
  387. Symed Labs
  388. Syncom Healthcare 
  389. Systochem Laboratories
  390. Tahira Industries
  391. Taj Pharmaceuticals
  392. Takeda
  393. Tara Innovations
  394. Tegra Medical
  395. Teika Pharmaceutical
  396. Teligent
  397. Texas Therapeutics
  398. The Cleveland Clinic
  399. The Hong Kong Polytechnic University
  400. Titan Pharma
  401. Tonus-Les
  402. Torrent Pharmaceuticals 
  403. Trelleborg Sealing Solutions 
  404. Trumac Healthcare
  405. Unichem Laboratories
  406. Uni-Med India
  407. Union Quimico Farmacéutica
  408. Unison Pharmaceuticals
  409. University Health Network, Toronto
  410. University Hospital Center of Bordeaux  
  411. University of Alabama at Birmingham
  412. University of British Columbia
  413. University of California, Davis
  414. University of California, Los Angeles
  415. University of California, San Diego
  416. University of California, San Francisco
  417. University of Chicago
  418. University of Colorado, Denver
  419. University of Iowa
  420. University of Miami
  421. University of Michigan
  422. University of North Carolina, Chapel Hill
  423. University of Oxford
  424. University of Pittsburgh
  425. University of Rochester
  426. University of São Paulo
  427. University of Utah
  428. University of Waterloo
  429. University of Wisconsin, Madison
  430. University of Zurich
  431. URSAPHARM Arzneimittel
  432. USV
  433. Valentis Pharma
  434. Valtronic 
  435. VDASP Pharmaceuticals
  436. Vergo Pharma Research Laboratories
  437. VersaPharm 
  438. Vetter Pharma
  439. Viant Medical
  440. Vibcare
  441. Vienna Institute for Research in Ocular Surgery
  442. Vivimed 
  443. VxP Pharma
  444. Wanbury 
  445. Wannock pharmaceuticals
  446. Washington University School of Medicine
  447. Wenzhou Medical University
  448. Wills Eye Hospital
  449. Wintac
  450. Wockhardt
  451. Wuhu Sanyi Xincheng Pharmaceutical
  452. WuXi AppTec
  453. Xellia Pharmaceuticals
  454. Y S Lab
  455. Yale University
  456. YaoPharma
  457. Yonsei University
  458. Zenius
  459. Zenlabs
  460. Zylig Lifesciences
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com